Costs and benefits of non‐invasive fetal RhD determination
- 7 November 2014
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 45 (1) , 84-88
Abstract
Objective: Non‐invasive fetal Rhesus (Rh) D genotyping, using cell‐free fetal DNA (cffDNA) in the maternal blood, allows targeted antenatal anti‐RhD prophylaxis in unsensitized RhD‐negative pregnant women. The purpose of this study was to determine the cost and benefit of this approach as compared to routine antenatal anti‐RhD prophylaxis for all unsensitized RhD‐negative pregnant women, as is the current policy in the province of Alberta, Canada.Methods: This study was a decision analysis based on a theoretical population representing the total number of pregnancies in Alberta over a 1‐year period (n = 69 286). A decision tree was created that outlined targeted prophylaxis for unsensitized RhD‐negative pregnant women screened for cffDNA (targeted group) vs routine prophylaxis for all unsensitized RhD‐negative pregnant women (routine group). Probabilities at each decision point and costs associated with each resource were calculated from local clinical and administrative data. Outcomes measured were cost, number of women sensitized and doses of Rh immunoglobulin (RhIG) administered.Results: The estimated cost per pregnancy for the routine group was 71.43 compared with 67.20 Canadian dollars in the targeted group. The sensitization rates per RhD‐negative pregnancy were equal, at 0.0012, for the current and targeted programs. Implementing targeted antenatal anti‐RhD prophylaxis would save 4072 doses (20.1%) of RhIG over a 1‐year period in Alberta when compared to the current program.Conclusions: These data support the feasibility of a targeted antenatal anti‐RhD prophylaxis program, at a lower cost than that of the existing routine prophylaxis program, with no increased risk of sensitization. Copyright © 2014 ISUOG. Published by John Wiley & Sons Ltd.Keywords
Funding Information
- Department of Obstetrics and Gynecology University of Calgary
This publication has 24 references indexed in Scilit:
- Costs and Clinical Outcomes of Noninvasive Fetal RhD Typing for Targeted ProphylaxisObstetrics & Gynecology, 2013
- Report of the first nationally implemented clinical routine screening for fetal RHD in D− pregnant women to ascertain the requirement for antenatal RhD prophylaxisTransfusion, 2011
- Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS)Headache: The Journal of Head and Face Pain, 2011
- Fetal RHD Genotyping in Maternal Plasma at 11–13 Weeks of GestationFetal Diagnosis and Therapy, 2011
- Noninvasive Fetal Blood Grouping: Present and FutureClinics In Laboratory Medicine, 2010
- Microfluidics Digital PCR Reveals a Higher than Expected Fraction of Fetal DNA in Maternal PlasmaClinical Chemistry, 2008
- Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility studyBMJ, 2008
- Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell‐free fetal DNA in maternal plasmaTransfusion, 2007
- Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood—A meta-analysisAmerican Journal of Obstetrics and Gynecology, 2006
- Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune GlobulinNew England Journal of Medicine, 1999